Gilead Sciences
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
Gilead Optimistic About 11 Percent Q2 Growth in Cell Therapy Sales but Readying for Competition
Premium
The firm is working with providers to expand the use of Yescarta and Tecartus as competition from other CAR T-cell therapies and bispecifics heats up.
The firm is encouraged by the MAT2A inhibitor's commercial prospects after seeing its efficacy as a monotherapy in some MTAP-null bladder and lung cancer patients.
Ideaya Begins Testing MAT2A Inhibitor, Trodelvy in Phase I MTAP-Deleted Bladder Cancer Study
The firm will also begin studying the activity of IDE397 monotherapy in the same indication in a Phase II expansion cohort.
Gilead, Arcellx Outline Plans for Phase III Anito-Cel Multiple Myeloma Trial
The partners will compare the activity of the BCMA-directed autologous CAR T-cell therapy against standard treatment in refractory patients.
Aug 4, 2023